Prostate Cancer Trial, Recruiting NCT06600802 Sponsor: Centre Jean Perrin Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06600802
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male and older than 18 years of age
  • You are able to carry out basic daily activities with minimal or no limitations (confirm with trial site regarding activity level assessment)
  • You have been diagnosed with prostate cancer that has spread to other parts of the body and is no longer responding to hormone-lowering treatments, confirmed by a tissue sample (biopsy or removed prostate tissue)
  • You have previously been treated with at least one chemotherapy regimen containing taxane drugs, and at least one newer type of hormone therapy
  • You are currently receiving treatment to lower testosterone levels, with very low testosterone in your blood, or you have had surgical removal of the testicles
  • Your prostate cancer is getting worse, shown by rising PSA blood test levels over time, new or growing tumours on scans, or new spots appearing on bone scans
  • You have at least one area where cancer has spread (to bones, lymph nodes, or organs), confirmed by scans taken within the last 43 days before joining the trial
  • A special scan called a PSMA PET scan confirms that your cancer is suitable for a type of treatment that targets the PSMA protein on cancer cells
  • Your blood counts, liver, and kidneys are working well enough to safely participate (confirm specific levels with trial site)
  • You are able to give your free and informed agreement to take part in the trial
  • You are covered by a social security or health insurance scheme (confirm with trial site, as this may be specific to the country where the trial is running)

Who may not be able to join:

  • You are currently still taking a newer type of hormone therapy drug
  • You have had another type of cancer in the past 3 years that could affect your life expectancy or make it hard to assess your prostate cancer
  • You are a legally protected adult (confirm with trial site)
  • You have a physical or mental health condition that could interfere with the study's goals or assessments
  • You are unable to understand or follow the study's instructions and requirements
  • Your general health and ability to do daily activities is significantly limited (confirm with trial site regarding activity level assessment)
  • You have a blockage or swelling in the tubes connecting your kidneys to your bladder that has not been treated
  • You have a blocked bladder outlet or uncontrollable urinary leakage at the same time
  • You have symptoms of pressure on your spinal cord, or scans suggest this could happen soon
  • You have bones at high risk of breaking due to your cancer
  • You have active and symptomatic cancer that has spread to the brain
  • You are currently taking part in another clinical trial, or have taken an experimental treatment within 28 days before joining this trial
  • The only tissue sample available for your prostate cancer diagnosis comes from a spread (metastatic) site rather than the prostate itself
  • You have received certain types of bone-targeting radiation treatments (such as Radium-223 or similar) within the 6 months before joining the trial
  • You have previously been treated with any radioactive drug that targets the PSMA protein
  • You have a known allergy or sensitivity to any of the treatments used in this trial or similar drugs
  • You have recently had a blood transfusion or received bone marrow stimulating injections specifically to meet the blood count requirements for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0473278005

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Jean Perrin
Registry
ClinicalTrials.gov
Start date
8 October 2024
Est. completion
30 June 2034

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Molecular abnormalities retained on primary tumor sample predicting response to Lu-PSMA in metastatic castration resistant prostate cancer patients assessed according to RECIST 1.1 and/or PCWG3 criteria

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov